Calcineurin inhibitor (CNI) withdrawal + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI
Adverse events: malignancy · kidney transplant recipients
Calcineurin inhibitor (CNI) withdrawal + mammalian target of… showed no clear difference in adverse events: malignancy compared with standard dose CNI (low certainty).
1 finding from 1 review
- Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes onlyRR 0.69 [0.47, 1]14 studies · 3699 participantsLow